

FIG. I





FIG. 2A


FIG. 2B

FR3T3 Ras



WT



A63/73



HeLa



Jurkat





FIG. 3A

In Vitro



In Vivo




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5A

FIG. 5B





FIG. 5C


Protein Gel

FIG.6A



**^{32}P -Immobilized
Substrate**

FIG.6B



**^{32}P -Exogenous
Substrate**

FIG.6C






FIG. 7A




FIG. 7B



FIG. 7C




FIG. 9A




FIG. 9B




FIG. II B

FIG. II A

FIG. 12A





FIG. 12B






FIG.12C




FIG.13A




FIG.13B

FIG.13C




FIG. 14

CSA₊ CSA₊
- CSA T A T/A T/A MW.




FIG. 15A

Erk-1 Mut →

- 106
- 80
- 49.5
- 32.5

Erk-1 Mut →

MBP →
FIG. 15B




FIG. 15D
MBP →




FIG. 15C

- 106
- 80
- 49.5
- 32.5



FIG. 15D

FIG. 16A




FIG. 16B




FIG. 16C

	1	2	3	4	5	6	7	8	9	10	11
CsA	-	-	-	-	-	-	+	-	+	-	+
anti-CD28	-	-	-	-	+	-	-	-	-	+	+
anti-CD3	-	-	-	+	-	-	-	+	+	-	-
A	-	-	+	-	-	+	+	-	-	-	-
T	-	+	-	-	-	+	+	+	+	+	+

